JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishikawa, H.
Right arrow Articles by Otani, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishikawa, H.
Right arrow Articles by Otani, T.
Journal of the American College of Nutrition, Vol. 22, No. 1, 56-63 (2003)
Published by the American College of Nutrition

Original Research

Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis

Hideki Ishikawa, MD, Ikuko Akedo, MD, Yoshinori Umesaki, PhD, Ryuichiro Tanaka, MD, Akemi Imaoka, MS and Toru Otani, MD

Department of Cancer Epidemiology, Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (H.I., I.A., T.O.), JAPAN
Yakult Central Institute for Microbiological Research, Tokyo (Y.U., R.T., A.I.), JAPAN

Address reprint requests to: Hideki Ishikawa M.D., Laboratory of Hereditary Tumor, Institute for Advanced Medical Sciences, Hyogo College of Medicine, 3-1 Kyomachibori 2-chome, Nishi-ku, Osaka 550-0003, JAPAN. E-mail: cancer{at}gol.com

Background: Alterations of intestinal flora, such as reduction in the concentration of bifidobacteria and increase in that of Bacteroides species, are apparently associated with the severity of ulcerative colitis.

Objective: We conducted a randomised clinical trial of the use of a bifidobacteria-fermented milk (BFM) supplement as a dietary adjunct in the treatment of ulcerative colitis.

Methods: The subjects were randomly divided into two groups: a group with BFM supplementation (BFM group, 11 subjects) and a control group (control group, 10 subjects). The BFM group was given 100 mL/day of BFM for one year. Colonoscopies, general blood markers and examinations of intestinal flora including the analysis of fecal organic acids were performed at the commencement of the study and after one year.

Results: Exacerbation of symptoms was seen in 3 out of 11 subjects in the BFM group and in 9 out of 10 in the control group. Log rank statistic analysis of the cumulative exacerbation rates showed a significant reduction in exacerbations for the BFM group (p = 0.0184). The analysis of microflora and the organic acids in the feces showed a significant reduction in the relative proportion of B. vulgatus in Bacteroidaceae and butyrate concentration, respectively, after supplementation with BFM, in comparison with before.

Conclusion: Supplementation with the BFM product was successful in maintaining remission and had possible preventive effects on the relapse of ulcerative colitis.

Key words: ulcerative colitis, Randomised controlled trial, Bifidobacteria, Bacteroides vulgatus, short chain fatty acid




This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
J. O. Clarke and G. E. Mullin
A Review of Complementary and Alternative Approaches to Immunomodulation
Nutr Clin Pract, February 1, 2008; 23(1): 49 - 62.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Nutrition.